Study Product Return Re-Supply and Re-Issue MTN-003 Study-Specific Training.

Slides:



Advertisements
Similar presentations
1 MTN-003 Training Follow-up Visit Scheduling and Visit Coding SSP Sections and
Advertisements

Tips to a Successful Monitoring Visit
ASPIRE Off-Site Visits. Rationale Why make an allowance for off-site visits in the protocol? Adherence & Retention Off-site visits Improving Clinic Flow.
1 MTN-003 Study Specific Training Randomization Overview.
ASPIRE TRAINING RANDOMIZATION & INITIAL DISPENSING Cindy Jacobson, PharmD (MTN) Jen Berthiaume/Missy Cianciola (SCHARP)
Study Product Adherence Counseling At Follow-up Visits
SecureVault SecureVault DUMC North Central Pharmacy: First Dose TRAINING MODULE: 1 DUMC NCP.
Contraception Counseling Considerations MTN-003 Study-Specific Training.
Coding Clinical Encounters. Definition of Terms: CPT E/M and Procedure Codes The CPT E/M section is divided into broad categories such as office visits,
School Name Here 2010 NECAP Science Test Administrator Workshop.
01 18 th March 2013 Investigator Meeting STAKT - Drug supply.
Study Product Adherence Counseling At Enrollment MTN-003 Study-Specific Training.
ERSEA Training April 17, /17/2015
1 MTN-003 Training General Interviewing Techniques Some specific tips for administering the Screening interviewer-administered CRFs SSP Section 14.
1 MTN 003 Data Management Considerations SSP Sections 14, 15 & 17.
ASPIRE TRAINING Study Product Considerations & Accountability for Non-Pharmacy Staff.
Training Requirements Virginia Department of Health Summer Food Service Program (SFSP) 2014.
Monitoring Requirements Virginia Department of Health Summer Food Service Program (SFSP) 2014.
For Medication Certified Staff Members Only.   Governs how we give medications in a school setting  States that each parish will develop, follow and.
MTN-028 Study Product Considerations Cindy Jacobson Lindsay Kramzer Microbicide Trials Network.
Coordinator University Clinical Research Pharmacy Investigational Drug Service (IDS) Marjorie Shaw Phillips, MS, RPh, FASHP Clinical Research Pharmacist.
MTN-028 Product Management Flow Charts Temporary Holds Permanent Discontinuations.
CC-CVE Instructional Methodologies Overview, Definitions, Requirements, and Responsibilities.
MODULE I Close-Out Visit/Monitoring Reports Jane Fendl April 24, Versions: Final 24-Apr-2010.
Product Use Management MTN 020 Training. Objectives- study product tab  Identify the conditions that would require a product hold or discontinuation.
MTN-027 Study Product Considerations Cindy Jacobson Microbicide Trials Network Pittsburgh, PA USA.
Overview of medication issues and administration of medications in school Adebola E. Orimadegun.
April 15 th is not just the deadline for your taxes!!! Is your documentation complete for Pharmacist to Registered Technician Ratios? Policies.
Participant Accrual. Numbers that Matter 3476= total number of women enrolled at least 95% retention at each visit, at each study site 100% attention.
RDA/cb/2010 Training Objectives  Be familiar with New Mexico Statewide Assessment Programs  Understand test security and training requirements  Know.
AE/SAE/EAE Identification and Reporting AE/SAE/EAE Identification and Reporting.
Follow-up Visit Procedures MTN-028 Study Specific Training.
Informed Consent Process: Key Considerations. Introduction  Informed consent is a requirement of ethical clinical research  Section 4.8 of the International.
Medication Assistant Test Modules #2, #3, and #4.
Participant Retention Plans MTN-003 Study-Specific Training.
EAE Training EAE Reporting and Assessment Overview DAIDS Regional Training Event, Regulatory Compliance Center Kampala, Uganda, September 2009 DAIDS Regional.
After School Snack Program Training Provided by the LAUSD Food Services Division
Use of Safety Monitoring Flow Sheets. Background  Flow sheets can serve as useful tools  Not required but recommended  Tailor for ease of use AND usefulness.
**INSERT YOUR TITLE HERE**
CTMB Guidelines (Rev. October 2006) Section 5: Conducting the Quality Assurance Audit.
Mrs. Sills, Placement Specialist Holland Public Schools Please sign in and write down your address (clearly) so that I can contact you easier (won’t.
IP Accountability in Outpatient Clinical Trials
Protocol Deviations. MTN protocol deviation policy  MTN has recently revised their policy on PDs- this policy will be made available on the MTN website.
CONDUCTING COMPLIANCE ASSESSMENTS Allen Ditch Director Corporate Quality Bristol Myers Squibb Medical Research Summit March 6, 2003.
Attendance, Class Record Book and Enrollment Counts
MTN-025/HOPE Decliner Population Procedures. Who are the Decliner Population? Former ASPIRE participants who decline or express no interest in joining.
Protocol Requirements for Product Holds/Discontinuations MTN-025.
1 HOPE Product Use Management: HIV Infection no rapid test(s) positive CONTINUE product. HOLD product pending confirmatory testing. PERMANENTLY DISCONTINUE.
Sponsor Visits and Monitoring Barbara Gallagher, RN Clinical Research Nurse Jefferson Clinical Research Institute.
April 15th is not just the deadline for your taxes
Planning for HOPE PUEVs and Study Exit Visits
HOPE SSP Updates May 2017.
Management of Pregnancies
Off-Site Visit Procedures and Documentation Considerations
Investigator of Record – Definition
Field Inventory Services-Sanofi Inventory and Audit Training
Protocol References Section Title 6.2 Entry Visit 5.1
HOPE STUDY PRODUCT TRAINING PHASE 2
Protocol References Section Title 6.2 Entry Visit 5.1
Batch Prescribing Repeat Dispensing
IMPAACT 2010 Pharmacy, Study Drug, and Concomitant Medication Considerations at Entry No updates.
MTN-026 Study Product Considerations
MTN-037 Study Product Considerations
Protocol Requirements for Product Holds/ Discontinuations
Investigator of Record – Definition
Investigator of Record – Definition
Participant Retention
Audit Pharmacy Review Rosalyn D. Williams
HOPE STUDY PRODUCT TRAINING
Good clinical practice
Presentation transcript:

Study Product Return Re-Supply and Re-Issue MTN-003 Study-Specific Training

Overview of Presentation Some Definitions Some Definitions Review of Visit Flow Review of Visit Flow Study Product Return Study Product Return Study Product Hold/Discontinuation Study Product Hold/Discontinuation Study Product Re-Supply Study Product Re-Supply Study Product Re-Issue Study Product Re-Issue Some Examples for Discussion Some Examples for Discussion

Definitions Study Product Return Study Product Return Refers to participants bringing their unused study product to follow-up visits for counting at the site pharmacy Refers to participants bringing their unused study product to follow-up visits for counting at the site pharmacy Returned product may either be retained in the pharmacy or re-issued to the participant Returned product may either be retained in the pharmacy or re-issued to the participant

Definitions Study Product Re-Supply Study Product Re-Supply Refers to dispensing new supplies of study product Refers to dispensing new supplies of study product Tablets re-supplied in quantities of 30 Tablets re-supplied in quantities of 30 Gel usually re-supplied in quantities of 30 but may be re-supplied in quantities of 10 or 20 Gel usually re-supplied in quantities of 30 but may be re-supplied in quantities of 10 or 20

Definitions Study Product Re-Issue Study Product Re-Issue Refers to providing participants with their own previously returned study product Refers to providing participants with their own previously returned study product

Visit Flow

Study Product Return Participants instructed to bring all unused product to all visits Participants instructed to bring all unused product to all visits Pharmacy staff count returned product and determine quantity: Pharmacy staff count returned product and determine quantity: Expected to be returned Expected to be returned Actually returned Actually returned Available for re-issue Available for re-issue

Product Eligible for Re-Issue Pharmacy staff will determine based on factors such as: Pharmacy staff will determine based on factors such as: Physical condition Physical condition Expiry Dates Expiry Dates Oral: 30 days after bottle is opened Oral: 30 days after bottle is opened Gel: 60 days after dispensed Gel: 60 days after dispensed Indicated by “do not use after” date Indicated by “do not use after” date Key counseling message: Use re-issued product first

Comments: Comments: Only four of each tablet are available for re-issue before the “do not use after” date (2 APR 2010). Remind participant to take re-issued product first, then open new bottles.

Comments: Comments: All of the tablets returned are in good condition. However, an unequal number of TDF/placebo and FTC/TDF or placebo were returned, therefore the most available for re-issue is 2 of each tablet.

4 0 0 Comments: Comments: Four gels were expected to be returned, but none were actually returned. Participant stated she did not accidentally leave at home, but suspects that her sister may have used some of her gels.

1 4 2 Comments: Comments: Of 4 gels returned, 2 were damaged. Therefore only 2 applicators are available for re-issue

Study Product Return Clinic staff use information recorded on the Study Product Returns Form to Clinic staff use information recorded on the Study Product Returns Form to Guide adherence counseling Guide adherence counseling Guide the ordering of study product to be re-supplied and re-issued Guide the ordering of study product to be re-supplied and re-issued

Study Product Re-Supply At each follow-up visit, authorized clinic staff must assess participant eligibility to continue product use At each follow-up visit, authorized clinic staff must assess participant eligibility to continue product use For those NOT eligible, product use is temporarily held or permanently discontinued For those NOT eligible, product use is temporarily held or permanently discontinued Document fully in participant’s clinic records Document fully in participant’s clinic records Inform pharmacy Inform pharmacy

Study Product Retrieval For participants NOT eligible to continue product use, product retrieval may be required, if participant did not bring all unused product to her visit For participants NOT eligible to continue product use, product retrieval may be required, if participant did not bring all unused product to her visit Retrieval may be done by Retrieval may be done by Participant returning product Participant returning product Study staff conducting outreach to retrieve product from participant Study staff conducting outreach to retrieve product from participant

Study Product Retrieval See protocol Section 6.6 for retrieval requirements See protocol Section 6.6 for retrieval requirements 24 hours for HIV (oral & vaginal) 24 hours for HIV (oral & vaginal) 24 hours for Grade 3+ liver or renal toxicity (oral) 24 hours for Grade 3+ liver or renal toxicity (oral) otherwise 5-7 days working days (oral & vaginal) otherwise 5-7 days working days (oral & vaginal) Inform Protocol Safety Review Team if product not retrieved within timeframe Inform Protocol Safety Review Team if product not retrieved within timeframe

Study Product Re-Supply For participants eligible to continue product use, authorized clinic staff determine quantity of product needed until next visit For participants eligible to continue product use, authorized clinic staff determine quantity of product needed until next visit Usually 30-day supply Usually 30-day supply Up to 60-day supply permitted at IoR discretion Up to 60-day supply permitted at IoR discretion More than 60-day supply requires approval of DAIDS Medical Officer (see SSP Section 9) More than 60-day supply requires approval of DAIDS Medical Officer (see SSP Section 9)

Study Product Request Slip For signatures, follow local regulations on: For signatures, follow local regulations on: Staff authorized to “prescribe” vs “re-supply” Staff authorized to “prescribe” vs “re-supply” How often an authorized prescriber must sign How often an authorized prescriber must sign NB: Authorized prescriber must sign for all resumptions NB: Authorized prescriber must sign for all resumptions Document authorizations on staff roster and maintain current listings of staff in each category Document authorizations on staff roster and maintain current listings of staff in each category

Study Product Re-Issue For participants eligible to continue product use, authorized clinic staff determine quantity of product needed until next visit For participants eligible to continue product use, authorized clinic staff determine quantity of product needed until next visit Total amount = re-supply + re-issue Total amount = re-supply + re-issue To determine total amount, consider To determine total amount, consider Number of days until next visit Number of days until next visit Standard re-supply quantities (30 tablets/bottle; 10 gels/carton) Standard re-supply quantities (30 tablets/bottle; 10 gels/carton) Quantity available for re-issue Quantity available for re-issue

Ideal Quantity Unless specific concerns are identified by the IoR or designee, aim to provide the larger of these two quantities Unless specific concerns are identified by the IoR or designee, aim to provide the larger of these two quantities Quantity needed for daily use through the next scheduled visit date, plus 7 days Quantity needed for daily use through the next scheduled visit date, plus 7 days or or Quantity needed for daily use through the next target visit date, plus 7 days Quantity needed for daily use through the next target visit date, plus 7 days

Minimum Quantity At a minimum, participants must be provided with enough study product for daily use until their next scheduled study visit At a minimum, participants must be provided with enough study product for daily use until their next scheduled study visit Ideal is ideal, Ideal is ideal, minimum is required minimum is required

Study Product Re-Supply For example, if next visit is targeted to take place in 28 days, but is scheduled to take place in 29 days, aim to provide a 36-day supply (29+7=36) For example, if next visit is targeted to take place in 28 days, but is scheduled to take place in 29 days, aim to provide a 36-day supply (29+7=36) That is, ideally re-supply 30 and re-issue 6 if available from the participant’s returns That is, ideally re-supply 30 and re-issue 6 if available from the participant’s returns At a minimum, a 29-day supply is required At a minimum, a 29-day supply is required Remember Expiry: Instruct and counsel participant to use re-issued product first Remember Expiry: Instruct and counsel participant to use re-issued product first

Example #1 Today’s visit date = 1 SEP 09 Today’s visit date = 1 SEP 09 Unused Product Returns slip indicates 2 TDF and 2 TDF/FTC tablets available for re-issue Unused Product Returns slip indicates 2 TDF and 2 TDF/FTC tablets available for re-issue Target date for next visit is Sunday, 27 SEP 09 Target date for next visit is Sunday, 27 SEP 09 Scheduled date for next visit is Friday, 25 SEP 09 Scheduled date for next visit is Friday, 25 SEP 09 What is the ideal quantity of product to provide to the participant at today’s visit? What is the ideal quantity of product to provide to the participant at today’s visit? How much would you re-supply and how much would you re-issue? How much would you re-supply and how much would you re-issue?

Today’s visit date = 1 SEP 09 Today’s visit date = 1 SEP 09 The next visit’s Target Date is 27 SEP 09 The next visit’s Target Date is 27 SEP 09 What is the number of days from today to the target date? Example #1

SUNMONTUEWEDTHUFRISAT 12 Start Count Target Date Example #1

Today’s visit date = 1 SEP 09 Today’s visit date = 1 SEP 09 The next visit’s Scheduled Date is 25 SEP 09 The next visit’s Scheduled Date is 25 SEP 09 What is the number of days from today to the scheduled date?

SUNMONTUEWEDTHUFRISAT 12 Start Count Scheduled Date Example #1

Today’s visit date = 1 SEP 09 Today’s visit date = 1 SEP 09 The next visit’s Target Date is 27 SEP 09 (26 days from today) The next visit’s Target Date is 27 SEP 09 (26 days from today) The next visit’s Scheduled Date is 25 SEP 09 (24 days from today) The next visit’s Scheduled Date is 25 SEP 09 (24 days from today) What is the ideal quantity of product to provide to the participant at today’s visit?

SUNMONTUEWEDTHUFRISAT 12 Start Count Target Date Example #1 Correct answer 26+7=33

Example #1 Today’s visit date = 1 SEP 09 Today’s visit date = 1 SEP 09 Unused Product Returns Form indicates 2 TDF and 2 TDF/FTC tablets available for re-issue Unused Product Returns Form indicates 2 TDF and 2 TDF/FTC tablets available for re-issue The next visit’s Target Date is 27 SEP 09 The next visit’s Target Date is 27 SEP 09 The next visit’s Scheduled Date is 25 SEP 09 The next visit’s Scheduled Date is 25 SEP 09 The ideal quantity of product to provide is 33 The ideal quantity of product to provide is 33 How much would you re-supply and how much would you re-issue? 1. Re-supply 2, Re-issue Re-supply 3, Re-issue Re-supply 31, Re-issue 2 4. Re-supply 30, Re-issue 2

Example #2 Today’s visit date = 1 SEP 09 Today’s visit date = 1 SEP 09 Unused Product Returns Form indicates 8 applicators available for re-issue Unused Product Returns Form indicates 8 applicators available for re-issue The next visit’s Target Date is Saturday, 26 SEP 09 The next visit’s Target Date is Saturday, 26 SEP 09 The next visit’s Scheduled Date is Monday, 28 SEP 09 The next visit’s Scheduled Date is Monday, 28 SEP 09 What is the ideal quantity of product to provide to the participant at today’s visit? What is the ideal quantity of product to provide to the participant at today’s visit? How much would you re-supply and how much would you re-issue? How much would you re-supply and how much would you re-issue?

Today’s visit date = 1 SEP 09 Today’s visit date = 1 SEP 09 The next visit’s Target Date is 26 SEP 09 The next visit’s Target Date is 26 SEP 09 What is the number of days from today? Example #2

SUNMONTUEWEDTHUFRISAT 12 Start Count Target Date Example #2

Today’s visit date = 1 SEP 09 Today’s visit date = 1 SEP 09 The next visit’s Scheduled Date is 28 SEP 09 The next visit’s Scheduled Date is 28 SEP 09 What is the number of days from today?

SUNMONTUEWEDTHUFRISAT 12 Start Count Scheduled Date Example #2

Today’s visit date = 1 SEP 09 Today’s visit date = 1 SEP 09 The next visit’s Target Date is 26 SEP 09 The next visit’s Target Date is 26 SEP 09 The next visit’s Scheduled Date is 28 SEP 09 The next visit’s Scheduled Date is 28 SEP 09 What is the ideal quantity of product to provide to the participant at today’s visit?

SUNMONTUEWEDTHUFRISAT 12 Start Count Example #2 Correct answer 27+7=34 Scheduled Date

Example #2 Today’s visit date = 1 SEP 09 Today’s visit date = 1 SEP 09 Unused Product Returns Form indicates 8 applicators available for re-issue Unused Product Returns Form indicates 8 applicators available for re-issue The next visit’s Target Date is 26 SEP 09 The next visit’s Target Date is 26 SEP 09 The next visit’s Scheduled Date is 28 SEP 09 The next visit’s Scheduled Date is 28 SEP 09 How much would you re-supply and how much would you re-issue? 1. Re-supply 26, Re-issue 8 2. Re-supply 4, Re-issue Re-supply 30, Re-issue 4 4. Re-supply 30, Re-issue 8

Example #3 Today’s visit date = 1 SEP 09 Today’s visit date = 1 SEP 09 Participant does not return any unused applicators but reports that she has an unopened carton of gel at home that she forgot to bring with her to the visit Participant does not return any unused applicators but reports that she has an unopened carton of gel at home that she forgot to bring with her to the visit Target date for next visit is Saturday, 26 SEP 09 (number of days from today = ___ ) Target date for next visit is Saturday, 26 SEP 09 (number of days from today = ___ ) Scheduled date for next visit is Monday, 28 SEP 09 (number of days from today = ___ ) Scheduled date for next visit is Monday, 28 SEP 09 (number of days from today = ___ ) How will you handle this situation? How will you handle this situation? 25 27

Example #4 Unused Product Returns slip indicates 4 TDF and 4 TDF/FTC tablets available for re-issue Unused Product Returns slip indicates 4 TDF and 4 TDF/FTC tablets available for re-issue Target Date is in 28 days Target Date is in 28 days Scheduled Date is in 37 days Scheduled Date is in 37 days What is the ideal and minimum quantity to supply? 1. Ideal 35, Minimum Ideal 35, Minimum Ideal 44, Minimum Ideal 44, Minimum 30

Example #4 Ideal 44, Minimum 37 Ideal 44, Minimum 37 Four of each tablet available for re-issue Four of each tablet available for re-issue How might you handle this situation? How might you handle this situation? Consider re-scheduling participant Consider re-scheduling participant Up to 60-day supply permitted at IoR discretion Up to 60-day supply permitted at IoR discretion More than 60-day supply requires approval of DAIDS Medical Officer More than 60-day supply requires approval of DAIDS Medical Officer Can always consult the PSRT Can always consult the PSRT

Scheduled Minimum Ideal Print 2 copies: - File one in participant binder - Send one to pharmacy with study product request slip

What Are Your Questions?